Company intelligence / Profile preview
Pure Biologics
Wroclaw, Polandpurebiologics.com ↗
- Ownership
- Private
- Employees
- ~51
- Development stage
- Preclinical
01
Overview
Pure Biologics has initiated patient recruitment for a Phase 0 clinical study in project PB003G. The company’s pipeline includes preclinical and early-stage programs focused on novel antibody and aptamer-based therapies targeting immuno-oncology and rare autoimmune/neurological indications. No late-stage or commercialized products reported as of May 2025
- Therapeutic areas
- OncologyImmunologyNeurologyNephrology
- Modalities
- Antibodiesaptamers (including therapeutic and diagnostic aptamers)biological drugs
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Not specifically listed by name in public sources; the company collaborates with pharmaceutical and biotechnology companies via contract research services
Beyond the preview
Go deeper on Pure Biologics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pure Biologics.